Last reviewed · How we verify
Metronidazole 0.75% Topical Gel
Metronidazole 0.75% Topical Gel is a Small molecule drug developed by University of Iowa. It is currently FDA-approved.
At a glance
| Generic name | Metronidazole 0.75% Topical Gel |
|---|---|
| Sponsor | University of Iowa |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Pharmacokinetics of Transdermal Metronidazole (PHASE4)
- Preferences & Treatment Satisfaction Drivers in Rosacea Patients
- Locally Delivered Antibiotics for the Treatment of Periodontitis (NA)
- Study to Evaluate the Efficacy and Safety of PAC-14028 Cream in Rosacea Patients (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Metronidazole 0.75% Topical Gel CI brief — competitive landscape report
- Metronidazole 0.75% Topical Gel updates RSS · CI watch RSS
- University of Iowa portfolio CI
Frequently asked questions about Metronidazole 0.75% Topical Gel
What is Metronidazole 0.75% Topical Gel?
Metronidazole 0.75% Topical Gel is a Small molecule drug developed by University of Iowa.
Who makes Metronidazole 0.75% Topical Gel?
Metronidazole 0.75% Topical Gel is developed and marketed by University of Iowa (see full University of Iowa pipeline at /company/university-of-iowa).
What development phase is Metronidazole 0.75% Topical Gel in?
Metronidazole 0.75% Topical Gel is FDA-approved (marketed).